Abstracts

Carlotta Giani, Liborio Torregrossa, Eleonora Molinaro et al. · European Thyroid Journal · 2014

Objectives: Lenvatinib is an oral multikinase inhibitor of VEGFR1-3, FGFR1-4, PDGFR , RET and KIT.This analysis reports detailed outcomes from the phase 3 Study of (E7080) LEnvatinib in Differentiated Cancer of the Thyroid (SELECT).Methods: Patients with documented progressive 131 I-refractory differentiated thyroid cancer (RR-DTC) within 13 months were randomized (2:1) in this double-blind, multicenter study to lenvatinib or placebo (24 mg/d; 28-d cycle).Primary endpoint was progression-free survival (PFS); secondary endpoints included overall response rate (ORR; complete response [CR] + partial response [PR]), OS, and safety.Results: 392 Patients (median age 63.0 y; 51.0% male) were randomized.PFS was significantly prolonged with lenvatinib vs placebo; median PFS 18.3 months vs 3.6 months (hazard ratio [HR] 0.21; 95% confidence interval [CI] 0.14-0.31;P < 0.0001).Lenvatinib PFS benefit was maintained in all predefined subgroups; median lenvatinib PFS for patients with prior vs no prior anti-VEGF pathway therapy was 15.1 months (95% CI 8.8-not reached [NR]) and 18.7 months (95% CI 16.4-NR), respectively.Exploratory analyses suggest lenvatinib PFS benefit is also maintained in subgroups including patients with lung metastasis (median PFS: lenvatinib, 18.7 months; placebo, 3.6 months; HR 0.21; 95% CI 0.15-0.29)and bone metastasis only (median PFS: lenvatinib, NR; placebo, 7.4 months; HR 0.65; 95% CI 0.11-4.07).Rates of CRs for lenvatinib: 1.5%; placebo: 0; PR for lenvatinib: 63.2%; pla

Cited by 15 works. doi:10.1159/000365244 Open-access PDF

Authors